| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00595-013-0674-6 |
| P698 | PubMed publication ID | 23887848 |
| P2093 | author name string | Joji Kitayama | |
| Hironori Ishigami | |||
| Hironori Yamaguchi | |||
| Toshiaki Watanabe | |||
| Taichi Ito | |||
| Shigenobu Emoto | |||
| Takao Kamei | |||
| Takashi Suhara | |||
| Yukimitsu Suzuki | |||
| P2860 | cites work | 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice | Q33647418 |
| Drug delivery systems for intraperitoneal therapy | Q33787894 | ||
| Environment-sensitive hydrogels for drug delivery | Q34463666 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents. | Q35009186 | ||
| Intraperitoneal antineoplastic drug delivery: rationale and results | Q35121705 | ||
| Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry | Q35385639 | ||
| The prevention of peritoneal adhesions by in situ cross-linking hydrogels of hyaluronic acid and cellulose derivatives | Q35768196 | ||
| CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells | Q35787027 | ||
| Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts | Q35855107 | ||
| Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors | Q35869447 | ||
| Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy | Q36040207 | ||
| Treatment of peritoneal carcinomatosis in gastric cancers | Q36090050 | ||
| Hyaluronan: pharmaceutical characterization and drug delivery | Q36299209 | ||
| Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment | Q36388620 | ||
| Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate. | Q36726713 | ||
| In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. | Q37102671 | ||
| Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer | Q37108665 | ||
| Recent results of therapy for scirrhous gastric cancer | Q37423169 | ||
| CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? | Q37851351 | ||
| Intraperitoneal drug delivery for ovarian cancer: why, how, who, what, and when? | Q37860283 | ||
| Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules. | Q39644922 | ||
| Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. | Q39654818 | ||
| The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model. | Q39674041 | ||
| Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice | Q39994801 | ||
| Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation | Q40098435 | ||
| Endothelial adhesion of synchronized gastric tumor cells changes during cell cycle transit and correlates with the expression level of CD44 splice variants. | Q40328279 | ||
| Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer | Q40554362 | ||
| Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate | Q40926266 | ||
| Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure | Q41404250 | ||
| A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells | Q42823728 | ||
| Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent | Q44091988 | ||
| Prolongation of sciatic nerve blockade by in situ cross-linked hyaluronic acid | Q44878469 | ||
| Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. | Q45928405 | ||
| New strategy for chemical modification of hyaluronic acid: preparation of functionalized derivatives and their use in the formation of novel biocompatible hydrogels | Q46065332 | ||
| In situ cross-linkable hyaluronic acid hydrogels prevent post-operative abdominal adhesions in a rabbit model | Q46462401 | ||
| Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer | Q50512108 | ||
| Peritoneal adhesion prevention with an in situ cross-linkable hyaluronan gel containing tissue-type plasminogen activator in a rabbit repeated-injury model | Q51000502 | ||
| Injectable hyaluronic acid microhydrogels for controlled release formulation of erythropoietin. | Q51111487 | ||
| Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
| Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery | Q57188694 | ||
| Drug release behaviors of a pH sensitive semi-interpenetrating polymer network hydrogel composed of poly(vinyl alcohol) and star poly[2-(dimethylamino)ethyl methacrylate] | Q59204700 | ||
| Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study | Q67520718 | ||
| Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin | Q69938967 | ||
| Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study | Q70790917 | ||
| Administration in a hypotonic solution is preferable to dose escalation in intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in rats | Q77961992 | ||
| Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma | Q80525690 | ||
| Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer | Q81924096 | ||
| pH effect on the synthesis, shear properties, and homogeneity of iron‐crosslinked hyaluronic acid‐based gel/adhesion barrier | Q84604206 | ||
| P433 | issue | 5 | |
| P921 | main subject | cisplatin | Q412415 |
| hydrogel | Q898925 | ||
| P304 | page(s) | 919-926 | |
| P577 | publication date | 2013-07-26 | |
| P1433 | published in | Surgery Today | Q15765823 |
| P1476 | title | Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer | |
| P478 | volume | 44 |
| Q35833966 | A novel approach of optical biopsy using probe-based confocal laser endomicroscopy for peritoneal metastasis. |
| Q35868066 | A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis |
| Q57347438 | Biocompatible poly(N-isopropylacrylamide)-g-carboxymethyl chitosan hydrogels as carriers for sustained release of cisplatin |
| Q37662249 | Cross-linked hyaluronic acid gel inhibits metastasis and growth of gastric and hepatic cancer cells: in vitro and in vivo studies |
| Q38183786 | Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer |
| Q91670635 | FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model |
| Q37346875 | Improved i.p. drug delivery with bioadhesive nanoparticles |
| Q35032664 | Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. |
| Q45873467 | MALAT2-activated long noncoding RNA indicates a biomarker of poor prognosis in gastric cancer |
| Q34093885 | MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin |
| Q47165034 | Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. |
| Q26995835 | Nanotechnology-based drug delivery systems for treatment of oral cancer: a review |
| Q92617961 | Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model |
| Q90754497 | Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer |
| Q54948378 | Slow-Release Formulation of Cowpea Mosaic Virus for In Situ Vaccine Delivery to Treat Ovarian Cancer. |
| Q57377230 | Synthesis of adipic acid dihydrazide-decorated coco peat powder-based superabsorbent for controlled release of soil nutrients |
| Q41462800 | The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients |
Search more.